Lineage Cell Therapeutics
LCTX
LCTX
58 hedge funds and large institutions have $57.6M invested in Lineage Cell Therapeutics in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
5% less capital invested
Capital invested by funds: $60.8M → $57.6M (-$3.22M)
82% less call options, than puts
Call options by funds: $27K | Put options by funds: $152K
Holders
58
Holding in Top 10
1
Calls
$27K
Puts
$152K
Top Buyers
| 1 | +$1.64M | |
| 2 | +$710K | |
| 3 | +$521K | |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$402K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$337K |
Top Sellers
| 1 | -$2.21M | |
| 2 | -$255K | |
| 3 | -$121K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$117K |
| 5 |
D.E. Shaw & Co
New York
|
-$93.8K |